Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the long-term follow-up and FREEDOM-1 trials of FCR-001.
"Both patients are now more than 12 months out from their transplant who received our therapy and are now off all chronic immunosuppression... We’ve also identified, in phase 2, chimerism as a biomarker, which we believe is potentially quite predictive of the long-term ability to get off and stay off immune suppression.”
Talaris Therapeutics’ ambitious goal is to be able to reprogram the immune system for a variety of immune indications. To this end, they are revolutionizing solid organ transplant with their lead program that chimerizesthe immune system to tolerate both donor and host cells.
Talaris’ lead program in living kidney transplant, another program in diffuse cutaneous systemic sclerosis (dcSSc), and a preclinical program in deceased kidney transplant all use their cell therapy candidate FCR-001. The company recently presented positive data from the phase 2 long-term follow-up study as well as the phase 3 FREEDOM-1 trial in living kidney transplant.
GeneTherapyLive spoke with Scott Requadt, chief executive officer, Talaris Therapeutics, to learn more about the trials the company is conducting in living kidney transplant. He discussed data from the phase 2 long-term follow-up and phase 3 FREEDOM-1 trials as well the use of chimerism within study participants as a biomarker of efficacy.